OS Therapies Inc President and CEO Paul A. Romness filed a Form 4 on October 30, 2026, reporting the grant of 900,000 stock options on October 22, 2026, with an exercise price of $1.25 per share.

Key Highlights

  • Reporting person: Paul A. Romness, President and CEO and Director of OS Therapies Inc (NASDAQ:OSTX)
  • Options granted: 900,000 stock options (right to buy) at an exercise price of $1.25 per share, acquired on October 22, 2026
  • Expiration date: October 22, 2036
  • Vesting schedule: 12 equal monthly installments beginning on each monthly anniversary of the grant date, subject to continued employment
  • Plan: Granted under the issuer's amended and restated 2023 incentive compensation plan
  • Common stock beneficial ownership following transaction: 2,473,000 shares (direct)
  • Derivative securities owned following transaction: 900,000 options (direct)

OS Therapies CEO Romness Receives Option Grant Under 2023 Incentive Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission on October 30, 2026, Paul A. Romness, who serves as both President and CEO and as a Director of OS Therapies Inc (NASDAQ:OSTX), reported the acquisition of stock options covering 900,000 shares of the company's common stock. The transaction date was October 22, 2026, with an exercise price of $1.25 per share and an expiration date of October 22, 2036.

The filing states that the options were granted "pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." The price of the derivative security at grant was listed as $0. The options are structured to vest in 12 equal installments on each monthly anniversary of the grant date, provided that Romness "is serving as an employee of the issuer on each applicable vesting date," according to the filing's explanation of responses.

Following the reported transaction, the filing shows Romness directly holds 2,473,000 shares of common stock and 900,000 stock options. No shares were disposed of in connection with this grant. The form was filed by one reporting person and was signed by Paul A. Romness on October 30, 2026.

What Was Disclosed

OS Therapies Inc President and CEO Paul A. Romness reported receiving a grant of 900,000 stock options at $1.25 per share on October 22, 2026, vesting monthly over 12 installments, under the company's amended and restated 2023 incentive compensation plan.